protein tyrosine phosphatase receptor type BGenealiases: HPTP-BETA · HPTPB · PTPB · R-PTP-BETA · VEPTP
Q-omics provides the consensus-scored PTPRB profile across patient tissues and cancer cell-line models. PTPRB expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PTPRB is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, PTPRB RNA expression shows 25,572 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUAD, and LSCC as cancer lineages where PTPRB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPRB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPRB survival associations across molecular data types. PTPRB RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPRB RNA expression–survival associations across cancer types. High PTPRB expression shows unfavorable associations in CESC, MESO, KIRP and UVM, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PTPRB RNA expression.
This table summarizes PTPRB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PTPRB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPRB shows lower tumor expression in LUAD, KIRP, KICH, LUSC, UCEC and BRCA. The LUAD box plot shows higher PTPRB RNA expression in normal versus tumor tissue (log2 FC = −2.993, t-test p < 0.001).
This table shows molecular features associated with PTPRB in patient tissues and cancer cell lines. In patient samples, PTPRB shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPRB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
